BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOCRYST PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.07+0.28 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $2.14B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
264M of 256M shares
Institutional holders
318
56 new, 37 sold out
Net institutional buying
23M
In Q2 2026
Insider trades, 12 months
0 buys · 10 sales
Net sold $4.14M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 17,483,490 | 8.40% | 13G (passive) amendment | Mar 31, 2025 |
| RA Capital Healthcare Fund, L.P. | 15,827,186 | 6.20% | 13G (passive) amendment | Jun 30, 2026 |
| Peter Kolchinsky | 15,302,186 | 7.30% | 13G (passive) | Nov 4, 2025 |
| State Street Corporation | 15,191,098 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Deerfield Management Company, L.P. | 14,341,000 | 6.81% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Capital Management | 12,961,172 | 5.16% | 13G (passive) | Mar 31, 2026 |
| James E. Flynn | 12,169,000 | 5.80% | 13G (passive) | Sep 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BCRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 23,893,036 | 9.35% | $238.93M | +1,242,048 | 0.00% |
| Ra Capital Management, L.P. | 15,827,186 | 6.19% | $158.27M | – | 1.38% |
| State Street Corp | 15,191,098 | 5.94% | $151.91M | +2,982,738 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 15,096,403 | 5.91% | $150.96M | +58,403 | 1.57% |
| Vanguard Capital Management LLC | 11,364,236 | 4.45% | $113.64M | +228,474 | 0.00% |
| Vanguard Portfolio Management LLC | 11,139,158 | 4.36% | $111.39M | −105,467 | 0.01% |
| TCG Crossover Management, LLC | 11,020,968 | 4.31% | $110.21M | – | 2.65% |
| Perceptive Advisors LLC | 10,308,888 | 4.03% | $103.09M | +2,874,855 | 1.55% |
| Jupiter Topco LLC | 9,540,764 | 3.73% | $95.27M | New | 0.04% |
| Vestal Point Capital, LP | 8,300,000 | 3.25% | $83.00M | +1,275,000 | 1.94% |
| Two Sigma Investments, LP | 6,775,349 | 2.65% | $67.75M | +382,721 | 0.05% |
| Geode Capital Management, LLC | 6,248,046 | 2.45% | $62.49M | +465,270 | 0.00% |
| abrdn plc | 5,310,871 | 2.08% | $53.11M | +270,201 | 0.07% |
| UBS Group AG | 5,078,280 | 1.99% | $50.78M | +134,286 | 0.01% |
| Bank Of America Corp /De/ | 4,801,284 | 1.88% | $48.01M | −290,481 | 0.00% |
| Goldman Sachs Group Inc | 4,481,874 | 1.75% | $44.82M | +2,134,431 | 0.00% |
| Frazier Life Sciences Management, L.P. | 4,009,240 | 1.57% | $40.09M | – | 0.87% |
| Nuveen, LLC | 4,007,237 | 1.57% | $40.07M | +187,974 | 0.01% |
| Nantahala Capital Management, LLC | 3,802,320 | 1.49% | $38.02M | +1,814,923 | 0.63% |
| Millennium Management LLC | 3,394,729 | 1.33% | $33.95M | +3,207,008 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 318 | 264M | 100.0% | 56 / 134 | 86 / 37 | 48M | 25M |
| Q1 2026 | 302 | 249M | 97.5% | 74 / 114 | 78 / 41 | 91M | 32M |
| Q4 2025 | 273 | 213M | 83.2% | 49 / 91 | 101 / 57 | 59M | 41M |
| Q3 2025 | 286 | 195M | 76.4% | 37 / 96 | 105 / 41 | 27M | 29M |
| Q2 2025 | 294 | 197M | 77.3% | 52 / 113 | 85 / 30 | 50M | 28M |
| Q1 2025 | 274 | 175M | 68.6% | 42 / 109 | 71 / 24 | 25M | 14M |
| Q4 2024 | 258 | 168M | 65.7% | 34 / 79 | 91 / 32 | 11M | 17M |
| Q3 2024 | 257 | 174M | 68.1% | 52 / 79 | 75 / 34 | 34M | 16M |
| Q2 2024 | 242 | 175M | 68.6% | 43 / 84 | 69 / 37 | 33M | 44M |
| Q1 2024 | 238 | 186M | 73.0% | 31 / 84 | 71 / 27 | 24M | 18M |
| Q4 2023 | 235 | 181M | 70.7% | 32 / 84 | 75 / 26 | 34M | 29M |
| Q3 2023 | 233 | 176M | 68.8% | 21 / 102 | 58 / 22 | 21M | 14M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BCRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 9,581,829 | 3.75% | $95.82M | 0.89% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 8,067,362 | 3.16% | $80.67M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,047,716 | 2.37% | $60.48M | 0.07% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,911,465 | 1.14% | $29.11M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,838,097 | 1.11% | $28.38M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,538,144 | 0.99% | $22.79M | 0.07% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 2,255,073 | 0.88% | $22.55M | 0.19% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 2,149,216 | 0.84% | $21.49M | 0.14% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,671,689 | 0.65% | $16.72M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,528,937 | 0.60% | $15.29M | 0.17% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 1,386,232 | 0.54% | $13.86M | 0.01% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,341,254 | 0.52% | $12.04M | 0.05% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 1,247,457 | 0.49% | $11.11M | 0.03% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,162,856 | 0.46% | $10.36M | 0.06% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,154,262 | 0.45% | $10.28M | 0.05% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alane P. Barnes | Chief Legal Officer | 463,203 | 0.18% | May 15, 2026 |
| Sandeep Menon | Chief R&D Officer | 205,150 | 0.08% | Apr 7, 2026 |
| Ronald Dullinger | Chief Commercial Officer | 258,372 | 0.10% | Jan 9, 2026 |
| Charles K. Gayer | President and CCO | 902,583 | 0.35% | Dec 23, 2025 |
| Babar Ghias | Chief Financial Officer | 268,700 | 0.11% | Dec 19, 2025 |
| Helen M. Thackray | Chief R&D Officer | 377,318 | 0.15% | Apr 2, 2025 |
| Anthony Doyle | Chief Financial Officer | 377,867 | 0.15% | Dec 23, 2024 |
| Amy E. McKee | Director | 47,821 | 0.02% | Sep 2, 2026 |
| Jon P. Stonehouse | Director | 1,420,419 | 0.56% | Sep 2, 2026 |
| Jill C. Milne | Director | 33,226 | 0.01% | Sep 2, 2026 |
| Vincent Milano | Director | 109,642 | 0.04% | Sep 2, 2026 |
| Steven Frank | Director | 36,747 | 0.01% | Sep 2, 2026 |
| Machelle Sanders | Director | 45,936 | 0.02% | Jun 15, 2026 |
| Alan G. Levin | Director | 79,565 | 0.03% | Jun 15, 2026 |
| Steven K. Galson | Director | 86,165 | 0.03% | Jun 15, 2026 |
| Theresa Heggie | Director | 80,646 | 0.03% | Jun 15, 2026 |
| Nancy J. Hutson | Director | 99,138 | 0.04% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jill C. Milne Director | Aug 31, 2026 | Award | +1,288 | $9.70 | $12.49K | 33,226 |
| Jon P. Stonehouse Director | Aug 31, 2026 | Award | +644 | $9.70 | $6.25K | 1,340,419 |
| Amy E. McKee Director | Aug 31, 2026 | Award | +644 | $9.70 | $6.25K | 47,821 |
| Steven Frank Director | Aug 31, 2026 | Award | +1,288 | $9.70 | $12.49K | 36,747 |
| Vincent Milano Director | Aug 31, 2026 | Award | +1,159 | $9.70 | $11.24K | 109,642 |
| Steven Frank Director | Jun 11, 2026 | Award | +15,294 | – | – | 35,459 |
| Jill C. Milne Director | Jun 11, 2026 | Award | +15,294 | – | – | 31,938 |
| Steven K. Galson Director | Jun 11, 2026 | Award | +15,294 | – | – | 27,794 |
| Theresa Heggie Director | Jun 11, 2026 | Award | +15,294 | – | – | 80,646 |
| Machelle Sanders Director | Jun 11, 2026 | Award | +15,294 | – | – | 45,936 |
| Vincent Milano Director | Jun 11, 2026 | Award | +15,294 | – | – | 108,483 |
| Jon P. Stonehouse Director | Jun 11, 2026 | Award | +15,294 | – | – | 1,339,775 |
| Alan G. Levin Director | Jun 11, 2026 | Award | +15,294 | – | – | 79,565 |
| Amy E. McKee Director | Jun 11, 2026 | Award | +15,294 | – | – | 47,177 |
| Jill C. Milne Director | May 29, 2026 | Award | +1,262 | $8.91 | $11.24K | 16,644 |
| Vincent Milano Director | May 29, 2026 | Award | +1,122 | $8.91 | $10.00K | 93,189 |
| Jon P. Stonehouse Director | May 29, 2026 | Award | +631 | $8.91 | $5.62K | 1,324,481 |
| Steven Frank Director | May 29, 2026 | Award | +1,262 | $8.91 | $11.24K | 20,165 |
| Amy E. McKee Director | May 29, 2026 | Award | +631 | $8.91 | $5.62K | 31,883 |
| Amy E. McKee Director | May 18, 2026 | Sale | −11,180 | $8.97 | $100.28K | 31,252 |
| Alane P. Barnes Chief Legal Officer | May 13, 2026 | Option exercise | +62,500 | $5.04 | $315.00K | 463,203 |
| Alane P. Barnes Chief Legal Officer | May 13, 2026 | Sale(10b5-1 plan) | −62,500 | $9.54 | $596.25K | 400,703 |
| Sandeep Menon Chief R&D Officer | Apr 6, 2026 | Award | +205,150 | – | – | 205,150 |
| Theresa Heggie Director | Mar 20, 2026 | Sale | −49,933 | $10.11 | $504.82K | 65,352 |
| Theresa Heggie Director | Mar 20, 2026 | Option exercise | +49,933 | $6.30 | $314.58K | 115,285 |
| Alane P. Barnes Chief Legal Officer | Mar 16, 2026 | Option exercise | +150,000 | $5.51 | $826.50K | 550,703 |
| Alane P. Barnes Chief Legal Officer | Mar 16, 2026 | Sale(10b5-1 plan) | −150,000 | $9.15 | $1.37M | 400,703 |
| Jon P. Stonehouse Director | Mar 2, 2026 | Option exercise | +305,995 | $3.22 | $985.30K | 1,629,845 |
| Jon P. Stonehouse Director | Mar 2, 2026 | Returned to company | −305,995 | $8.64 | $2.64M | 1,323,850 |
| Steven Frank Director | Feb 27, 2026 | Award | +1,285 | $8.75 | $11.24K | 18,903 |
| Amy E. McKee Director | Feb 27, 2026 | Award | +642 | $8.75 | $5.62K | 42,432 |
| Jon P. Stonehouse Director | Feb 27, 2026 | Award | +421 | $8.75 | $3.68K | 1,323,850 |
| Vincent Milano Director | Feb 27, 2026 | Award | +848 | $8.75 | $7.42K | 92,067 |
| Jill C. Milne Director | Feb 27, 2026 | Award | +528 | $8.75 | $4.62K | 15,382 |
| Jill C. Milne Director | Jan 23, 2026 | Award | +12,272 | – | – | 14,854 |
| Jill C. Milne Director | Jan 23, 2026 | Award | +2,582 | – | – | 2,582 |
| Alane P. Barnes Chief Legal Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −21,773 | $7.65 | $166.56K | 398,751 |
| Charles K. Gayer President and CCO | Dec 22, 2025 | Option exercise | +10,091 | $5.04 | $50.86K | 902,583 |
| Charles K. Gayer President and CCO | Dec 22, 2025 | Option exercise | +14,142 | $3.22 | $45.54K | 892,492 |
| Charles K. Gayer President and CCO | Dec 22, 2025 | Option exercise | +50,000 | $5.51 | $275.50K | 952,583 |
| Alane P. Barnes Chief Legal Officer | Dec 19, 2025 | Tax withholding | −16,902 | $7.41 | $125.24K | 420,524 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 19, 2025 | Tax withholding | −61,793 | $7.41 | $457.89K | 1,323,429 |
| Charles K. Gayer President and CCO | Dec 19, 2025 | Tax withholding | −11,477 | $7.41 | $85.04K | 878,350 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 18, 2025 | Gift | +10,000 | – | – | 40,000 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 18, 2025 | Gift | +10,000 | – | – | 40,000 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 18, 2025 | Gift | −20,000 | – | – | 1,385,222 |
| Charles K. Gayer President and CCO | Dec 17, 2025 | Award | +471,000 | – | – | 889,827 |
| Alane P. Barnes Chief Legal Officer | Dec 17, 2025 | Award | +121,700 | – | – | 437,426 |
| Babar Ghias Chief Financial Officer | Dec 17, 2025 | Award | +121,700 | – | – | 268,700 |
| Alane P. Barnes Chief Legal Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −21,210 | $7.65 | $162.26K | 315,726 |
| Charles K. Gayer President and CCO | Dec 12, 2025 | Tax withholding | −8,181 | $7.57 | $61.93K | 418,827 |
| Alane P. Barnes Chief Legal Officer | Dec 12, 2025 | Tax withholding | −8,540 | $7.57 | $64.65K | 336,936 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 12, 2025 | Tax withholding | −27,368 | $7.57 | $207.18K | 1,405,222 |
| Alane P. Barnes Chief Legal Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −19,770 | $7.65 | $151.24K | 345,476 |
| Alane P. Barnes Chief Legal Officer | Dec 2, 2025 | Sale(10b5-1 plan) | −50,906 | $7.21 | $367.03K | 365,246 |
| Alane P. Barnes Chief Legal Officer | Dec 1, 2025 | Sale(10b5-1 plan) | −91,004 | $7.10 | $646.13K | 416,152 |
| Alane P. Barnes Chief Legal Officer | Dec 1, 2025 | Option exercise | +91,004 | $3.22 | $293.03K | 507,156 |
| Steven Frank Director | Nov 28, 2025 | Award | +1,566 | $7.18 | $11.24K | 17,618 |
| Vincent Milano Director | Nov 28, 2025 | Award | +783 | $7.18 | $5.62K | 91,219 |
| Amy E. McKee Director | Nov 28, 2025 | Award | +783 | $7.18 | $5.62K | 41,790 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| McKee Amy Director | May 18, 2026 | 11,180 | $99.91K | May 18, 2026 | Stock Plan Activity |
| Alane P. Barnes Officer | May 13, 2026 | 62,500 | $596.25K | May 13, 2026 | Option Granted - 12/20/2017 |
| Theresa Heggie Director | Mar 20, 2026 | 49,933 | $504.62K | Mar 20, 2026 | Option Granted 06/12/2024 |
| Alane P. Barnes Officer | Mar 16, 2026 | 150,000 | $1.37M | Mar 16, 2026 | Option Granted - 02/27/2017 |
| Jon P. Stonehouse Director | Mar 2, 2026 | 305,995 | $2.65M | Mar 2, 2026 | Option Granted - 05/23/2016 |
| Alane P. Barnes Officer | Dec 22, 2025 | 21,773 | $166.56K | Dec 22, 2025 | Restricted Stock Vesting |
| Alane P. Barnes Officer | Dec 15, 2025 | 21,210 | $162.26K | Dec 15, 2025 | Restricted Stock Vesting |
| Alane P. Barnes Officer | Dec 3, 2025 | 19,770 | $151.24K | Dec 3, 2025 | Restricted Stock Vesting |
| Alane P. Barnes Officer | Dec 2, 2025 | 50,906 | $367.22K | Dec 2, 2025 | ESPP Purchase |
| Alane P. Barnes Officer | Dec 1, 2025 | 91,004 | $644.31K | Dec 1, 2025 | Option Granted - 05/23/2016 |
| M. Thackray Helen Officer | Nov 25, 2025 | 48,229 | $327.96K | Nov 25, 2025 | Stock plan activity |
| Thackray Helen Officer | Nov 21, 2025 | 43,275 | $307.69K | Nov 21, 2025 | Stock Plan Activity |
| Machelle Sanders Officer | Nov 13, 2025 | 9,600 | $68.54K | Nov 13, 2025 | Restricted Stock Vesting |
| Theresa Heggie Director | Aug 13, 2025 | 70,000 | $595.87K | Aug 13, 2025 | Option Granted - 05/29/2019 |
| Nancy J. Hutson Director | Dec 13, 2024 | 7,000 | $52.58K | Dec 13, 2024 | RSU Vesting under Stock Plan |